secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARINUS PHARMACEUTICALS, INC. (—)
CIK:        0001267813
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001104659-24-046976
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marinus RAISE trial interim analysis fails early stopping criteria; Q1 ZTALMY revenue $7.4-7.6M
--------------------------------------------------------------------------------

- DMC recommended continue RAISE; enrollment completed at ~100 patients; topline results summer 2024.
- Q1 2024 preliminary ZTALMY net revenue $7.4-7.6 million; cash $113.3 million as of March 31.
- TrustTSC enrollment expected mid-May; topline data on track for Q4 2024.
- Cost reduction activities under review to extend cash runway beyond Q4 2024.
- IV ganaxolone development for RSE to be reassessed after final RAISE results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/0001104659-24-046976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/tm2411822d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer